Teriparatide for low bone turnover in advanced kidney disease
Treatments studied
Part of Bones, joints & muscles, Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests teriparatide (a hormone-like bone medicine) to improve bone health in people with advanced chronic kidney disease who are at risk for weak, low-turnover bone. It may help by changing how quickly your bones break down and rebuild.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have advanced chronic kidney disease (stage 4–5, or on dialysis) with eGFR 29 or lower.
- Your bone density scan (DXA) shows low bone strength, or you’ve had a past fragility fracture.
- Your doctors expect “adynamic/low-turnover bone disorder,” based on blood tests (low bone-building marker) and/or a bone biopsy.
- Your calcium blood level is not consistently too high (high calcium can exclude you).
- You can safely take teriparatide and provide informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether regulating parathyroid hormone (PTH) can improve bone density in people with advanced chronic kidney disease (CKD) who are not on dialysis. It may help you if you have stage 4-5 CKD and high PTH levels.
This trial looks at a personalized approach to diagnosing and treating bone problems caused by long-term kidney disease. It may help by matching treatment plans to the type of bone turnover found in your tests or biopsy.
This study checks how kidney disease affects bone health by measuring hormones like PTH and related blood markers. It may help doctors better diagnose bone problems that can occur with poor kidney function.
This trial is studying whether the time of day you receive teriparatide (a bone-building drug) affects its effectiveness for postmenopausal women with osteoporosis. You may be eligible if you have very low bone density, are between 60 and 70, and are at least 5 years past your last period.
This trial tests whether a medication that helps build bone (Teriparatide) can improve healing after ankle fracture surgery in adults over 60 with certain health risks, such as diabetes or osteoporosis.
This trial tests teriparatide, a medication that helps build bone, to see if it can speed recovery and help certain enlisted Army members return to training duty after a tibia bone injury. You may be asked to self-administer the medication while you recover and take part in study follow-ups.
Hear when a new Cardiac Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.